Table 5.
Effect of inhibition of the cAMP-dependent PKA pathway on relaxations to VIP and rolipram and of activation of adenylate cyclase on the relaxations to VIP
| n | pD2 | Emax (%) | |
|---|---|---|---|
| VIP | |||
| Control | 7 | 8.06±0.06 | 80.6±7.1 |
| Rp-8-CPT-cAMPS (100 μM) | 7 | — | 50.3±5.6* |
| Control | 6 | 8.10±0.08 | 82.3±5.4 |
| Forskolin (30 nM) | 6 | 8.71±0.18* | 89.7±6.4 |
| Rolipram | |||
| Control | 6 | 7.64±0.12 | 78.5±7.5 |
| Rp-8-CPT-cAMPS (100 μM) | 6 | — | 48.5±7.2* |
The results are expressed as mean±s.e.m. of n experiments.
*
Parameter significantly (P<0.05) different compared (paired t-test) to the control value. Emax is the maximal relaxation, expressed as a percentage of the U46619-induced contraction, obtained for each drug. pD2=−log EC50, where EC50 is the concentration of agonist producing 50% of the Emax.